Literature DB >> 8159435

The dilemma of conversion from systemic to epidural morphine: a proposed conversion tool for treatment of cancer pain.

Stuart L Du Pen1, Anna R Williams.   

Abstract

There is lack of concensus over what constitutes an appropriate method to affect an equianalgesic conversion from systemic to epidural morphine. A systematic approach to calculate the appropriate starting dose for epidural morphine is needed. A model is proposed here and data from a pilot study are described supporting the concept as well as its utility in the clinical setting. Several key factors may have an impact upon the selection of a starting dose in the opioid-tolerant cancer population such as pain severity, age, previous systemic opioid use, and presence of neuropathic pain. A conversion tool was developed taking these 4 factors into account and was tested in a small number of patients with cancer pain. The rationale for this approach is explored. Four case examples are presented to demonstrate the utilization of the tool and the effectiveness of this formula for clinical practice. Further study is needed to firmly establish the validity and reliability of this tool.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8159435     DOI: 10.1016/0304-3959(94)90156-2

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  2 in total

1.  Intrathecal pain pump infusions for intractable cancer pain: an algorithm for dosing without a neuraxial trial.

Authors:  Vivek Tim Malhotra; James Root; Joseph Kesselbrenner; Innocent Njoku; Kenneth Cubert; Amitabh Gulati; Vinay Puttanniah; Mark Bilsky; Michael Kaplitt
Journal:  Anesth Analg       Date:  2013-04-04       Impact factor: 5.108

2.  Survey of pain specialists regarding conversion of high-dose intravenous to neuraxial opioids.

Authors:  Andrew W Gorlin; David M Rosenfeld; Jillian Maloney; Christopher S Wie; Johnathan McGarvey; Terrence L Trentman
Journal:  J Pain Res       Date:  2016-09-21       Impact factor: 3.133

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.